Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sen. Baucus Says Industry Is "Divided" Over Proposed Device Tax

This article was originally published in The Gray Sheet

Executive Summary

Sen. Max Baucus, D-Mont., suggested last week that a "fair" compromise on the amount device companies should contribute to health care reform is close at hand, but he expressed frustration that industry is not speaking with a single voice

You may also be interested in...



Conference Collaboration Sign Of Growing AdvaMed, MDMA Partnership

While the two US-based medical device lobby groups, AdvaMed and MDMA, may have butted heads in the past, they are showing an increasing level of cooperation, most recently with plans to partner on the upcoming Medtech Conference in San Jose.

St. Jude's Departure From AdvaMed Highlights Inherent Industry Tensions

St. Jude Medical CEO Daniel Starks has resigned from AdvaMed's board of directors and the company has left the organization, citing "strong dissent" over how to respond to proposed medical device fees in pending health reform legislation

St. Jude's Departure From AdvaMed Highlights Inherent Industry Tensions

St. Jude Medical CEO Daniel Starks has resigned from AdvaMed's board of directors and the company has left the organization, citing "strong dissent" over how to respond to proposed medical device fees in pending health reform legislation

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel